HAVCR2 and glioblastoma: Another clinical trial is testing the inhibition of TIM-3 (sabatolimab) and PD-1 (spartalizumab) together with stereotactic radiosurgery in recurrent GBM (NCT03961971) and IDO in combination with radiotherapy or TMZ [161,162].